MYOMO, INC.

Listed Company

MYOCIK 0001369290NYSENon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$40.93M

Net Income

$-15.57M

Total Assets

—

Equity

—

Shares Out

38.64M

Op. Cash Flow

$-14.51M

Business

MYOMO, INC. is a medical robotics company that develops and commercializes myoelectric-controlled upper limb orthoses to improve function for people with neuromuscular disorders and partial paralysis. It offers the MyoPro product line — custom‑fabricated, myoelectric elbow‑wrist‑hand braces incorporating EMG sensors, motors, software and 3D‑printed orthotic components — plus clinical training, remote evaluation tools, MyoGames and patient support services. The company operates as a single business segment centered on myoelectric limb orthotics and related software and services. It sells primarily in the United States through direct billing to payers, O&P providers and the VA, and distributes to select international markets including European countries, the U.K., Canada and Australia.

Summary from filing dated 2025-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	41	33	19	16	14
Cost of revenue	14	9	6	5	4
Gross profit	27	23	13	10	10
Research and development	7	5	3	2	3
Selling, clinical, and marketing	20	12	9	—	—
General and administrative	14	12	10	—	—
Total operating expenses	41	29	21	21	21
Loss from operations	−14	−6	−8	−11	−10
Other expense (income)	450,832	−388,586	−410,274	−88,731	−1,612
Loss on equity investment	216,673	0	169,503	66,511	0
Total other expense (income)	667,505	−388,586	−239,986	−21,119	15,336
Loss before income taxes	−15	−6	−8	−11	−10
Income tax expense	504,532	365,617	156,002	69,937	88,928
Net loss	−16	−6	−8	−11	−10
Basic (shares)	42	38	29	7	6
Diluted (shares)	42	38	29	7	6
Basic (per share)	−0.37	−0.16	−0.28	−1.52	−1.89
Diluted (per share)	−0.37	−0.16	−0.28	−1.52	−1.89

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	14	24	7	5	16
Short-term investments	4	492,990	2	0	—
Accounts receivable, net	4	4	2	2	2
Inventories	3	3	2	1	808,308
Prepaid expenses and other current assets	2	933,377	598,850	573,462	799,164
Total Current Assets	28	33	14	9	19
Restricted cash	575,000	375,000	0	—	—
Equipment, net	2	1	175,794	194,283	275,289
Software development costs	2	0	—	—	—
Operating lease assets with right-of-use, net	7	8	663,554	508,743	632,906
Other Assets	21,374	164,412	91,237	111,034	95,330
Total Assets	39	42	15	10	20
Accounts payable and accrued expenses	6	9	5	3	4
Current operating lease liability	494,662	748,021	486,143	353,701	333,380
Taxes payable	813,260	318,885	96,461	48,220	39,145
Deferred revenue	218,222	83,115	8,510	20,653	249
Warrant derivative liability	999,418	0	—	—	—
Total Current Liabilities	8	10	5	4	4
Non-current operating lease liability, net of current portion	8	7	115,160	200,207	401,622
Long-term debt, net of discount of $2,954,857	11	0	—	—	—
Total Liabilities	27	18	6	4	5
Commitments and Contingencies - Note 12	0	0	0	0	0
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0	0	0	0
Common stock par value $0.0001 per share 65,000,000 shares authorized; 38,471,383 and 34,378,297 shares issued as of December 31, 2025 and 2024, respectively, and 38,471,356 and 34,378,270 shares outstanding as of December 31, 2025 and 2024, respectively.	3,847	3,439	2,715	775	687
Additional paid-in capital	130	128	106	95	94
Accumulated other comprehensive (loss) income	164,517	−14,406	83,669	43,227	−60,677
Accumulated deficit	−119	−103	−97	−89	−78
Treasury stock, at cost; 27 shares of common stock	−6,464	−6,464	−6,464	−6,464	−6,464
Total Stockholders Equity	11	25	9	6	15
Total Liabilities and Stockholders Equity	39	42	15	10	20

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−16	−6	−8	−11	−10
Depreciation	859,354	205,910	164,306	192,799	145,995
Stock-based compensation	2	874,438	1	1	1
Accretion of discount on short-term investments	−43,012	−118,598	−110,788	0	—
Credit losses	158,012	43,657	28,401	26,075	0
Amortization of final payment fees of old debt	215,000	0	—	—	—
Amortization of right-of-use assets	905,314	571,061	353,375	349,828	189,968
Amortization of deferred offering cost	520,419	41,552	—	—	—
Change in fair value of derivative liabilities	216,673	0	—	—	—
Other non-cash changes, net	3,772	16,020	−38,809	111,755	−19,929
Accounts receivable	376,966	−2	−495,599	47,445	−1
Inventories	−662,680	−1	−384,781	−607,400	−118,222
Prepaid expenses and other current assets	−1	−887,525	−115,523	224,677	−323,644
Other assets	6,512	84,773	19,797	−15,704	0
Accounts payable and accrued expenses	−3	5	2	−711,898	1
Operating lease liabilities	54,079	−503,543	−460,790	−406,759	−92,525
Deferred revenue	135,108	74,604	−12,642	19,657	−2,512
Income tax payable	436,729	236,721	−47,384	0	—
Tenant improvement allowance	0	516,274	0	—	—
Net cash used in operating activities	−15	−3	−6	−10	−10
Purchases of equipment	−2	−1	−145,816	−111,793	−326,462
Purchases of software development	−2	0	—	—	—
Maturities of short-term investments	2	8	4	0	—
Purchases of short-term investments	−5	−6	−6	0	—
Net cash provided by (used in) investing activities	−7	259,981	−2	−310,793	−326,462
Deferred debt origination costs	0	−199,500	0	—	—
Proceeds from sale of pre-funded warrants, net of offering costs	0	763,138	0	0	1
Proceeds from sale of common stock and pre-funded warrants, net of offering costs	0	20	10	—	—
Repayment of debt	−4	0	—	—	—
Final payment fees of old debt	−215,000	0	—	—	—
Payment of debt issuance costs	−857,621	0	—	—	—
Proceeds from issuance of debt, revolving credit line	1	0	—	—	—
Proceeds from issuance of debt, term loan	3	0	—	—	—
Proceeds from issuance of debt, Avenue Capital	13	0	—	—	—
Net cash provided by financing activities	11	21	10	376,858	13
Effect of foreign exchange rate changes on cash	101,697	−26,439	14,211	−10,934	−10,392
Net increase in cash and cash equivalents	−10	18	2	−10	3
Cash paid during the period for income taxes	330,939	0	0	4,889	0
Cash paid during the period for interest	111,865	0	—	—	—
Right of use assets obtained in exchange for lease obligations	0	7	508,186	225,665	654,091
Unrealized (gain) loss from mark to market on short-term investments	922	165	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro